Form 4: Catalyst Pharmaceuticals Executive Reports Stock Transactions
SEC Form 4 Filing
Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and associated tax withholding.
Summary
- On December 27, 2024, Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, executed transactions involving the company's stock.
- Ingenito acquired 9,000 shares of common stock through the vesting of restricted stock units.
- The company withheld 3,541 shares to satisfy tax obligations related to the vesting.
- Following these transactions, Ingenito directly owns 61,308 shares of common stock.
- Ingenito also reports beneficial ownership of 1,025,282 derivative securities in the form of restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions, neither positive nor negative in itself.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives.
Key Dates
| Date | Description |
|---|---|
| 12/27/2023 | First tranche of restricted stock units vested (1/3rd). |
| 12/27/2024 | Second tranche of restricted stock units vested (1/3rd); shares delivered. |
| 12/27/2025 | Final tranche of restricted stock units vests (1/3rd). |
| 12/31/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.